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ABSTRACT 
 Here we report that bile acid chenodeoxycholic acid (CDCA) and synthetic farnesoid X 
receptor (FXR) agonist GW4064 robustly induced tumor suppressor N-Myc downstream 
regulated gene 2 (NDRG2) expression in human hepatoma cells and primary hepatocytes. 
Knockdown of FXR abolished the induction by CDCA, whereas overexpression of a 
constitutively active form of FXR increased NDRG2 expression. A FXR-response element was 
identified within intronic regions of human and murine genes. Moreover, mice given GW4064 
exhibit an increase of Ndrg2 expression in liver and kidney, where both NDRG2 and FXR are 
enriched. The identification of NDRG2 as a bile acid regulated gene may provide novel 
knowledge towards the understanding of NDRG2 physiological function and the link between 
metabolism and cancer. 
 
 
Keywords: bile acids; NDRG2; nuclear receptor; FXR; cancer; metabolism; kidney. 
 
Abbreviations: CDCA, chenodeoxycholic acid; EMSA, electrophoretic mobility shift assay; 
ENaC, epithelial sodium channel; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; I-
BABP, ileal-bile acid-binding protein; IR1, inverted repeat separated by a nucleotide; MOI, 
multiplicity of infection; NDRG2, N-myc downstream-regulated gene 2; PLTP, phospholipid 
transfer protein; QPCR, real-time quantitative PCR; RXR, retinoid X receptor; siRNA, small 
interfering RNA; SHP, small heterodimer partner; TK, thymidine kinase; TSS, transcription start 
site. 
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INTRODUCTION 
 N-myc downstream-regulated gene 2 (NDRG2) belongs to the NDRG family, comprised of 
four members, NDRG1-4, which are reportedly involved in cell proliferation and differentiation 
[1,2]. NDRG2 is highly expressed in many normal tissues, especially in the brain, heart, skeletal 
muscle, liver, and kidney, whereas low expressed or undetectable in a variety of human cancer 
cell lines and carcinomas [1,2]. Recently, NDRG2 was identified as a novel tumor metastasis 
suppressor in hepatocellular carcinoma (HCC) [3]. Although the precise molecular function of 
NDRG2 is not yet known, accumulated data indicate that low expression of NDRG2 may serve 
as a prognostic biomarker for malignant transformation in hepatocytes. In addition, it has been 
demonstrated that NDRG2 overexpression diminishes the proliferative, invasive and migratory 
abilities of HCC cells [3]. Thus, the identification of factors capable of inducing hepatic NDRG2 
expression may provide new opportunities for therapeutic intervention in liver cancer. 
Interestingly, Ndrg2 was initially characterized as an early aldosterone-induced gene in rat 
kidneys [4]. Thereafter, it was proposed that NDRG2 may affect the function of the epithelial 
sodium channel (ENaC) [5], which is localized in the apical membranes of sodium absorbing 
epithelia like the distal nephron and hence plays a key role in the maintenance of blood pressure. 
Consequently, the physiological role of NDRG2 may extend beyond cell proliferation. 
 The farnesoid X receptor  (FXR, NR1H4, hereafter referred to as FXR), a member of the 
nuclear hormone receptor superfamily, is the chief sensor of intracellular levels of bile acids [6]. 
FXR is highly expressed in the liver, kidney, intestine and the adrenal gland. In response to bile 
acid binding, FXR transcriptionally regulates a variety of genes involved in bile acid, lipid and 
glucose metabolism [6]. Since two independent groups reported that the loss of FXR in Fxr-null 
mice resulted in spontaneous hepatocarcinogenesis [7,8], considerable research efforts have been 
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focused on the identification of the underlying mechanisms of liver cancer inhibition by FXR 
and its relevance in the pathogenesis of human HCC. Subsequently, it has shown that FXR 
expression in human HCC samples was decreased compared to normal liver tissues [9]. 
Notwithstanding, the specific nature of the FXR target genes involved in the inhibition of liver 
cancer is still unknown. 
 
MATERIALS and METHODS 
Plasmids 
 A 2.4-kb fragment spanning from the 5’ flanking region to the second exon of Ndrg2 gene 
was amplified from genomic DNA using primers 5’-
TATCATAAGCGGCGGGACTCGGCTGAGGAG-3’ and 5’-
AGTCGCTAGCCTCCTGAAGTTCTGCAATGGTG-3’, KpnI/NheI digested, and subcloned 
into pGL3-basic vector (Promega) to obtain p-437/+1966NDRG2. Mutagenesis was performed 
using QuickChangeTM site-directed mutagenesis kit (Stratagene) with primers 5’-
GGGGAGATTAGAAAGAATTAGTGATTCTGGAATCCTGGGTCTTGGC-3’ and 5’-
GCCAAGACCCAGGATTCCAGAATCACTAATTCTTTCTAATCTCCCC-3’. Reporter 
plasmids p(NDRG2IR1)n-TK (n = 1, 2, 4) were generated by insertion of an oligonucleotide 
obtained by annealing 5’-GATCCTTAGAAAGGGTTAGTGACCCTGGAA-3’ and 5’-
GATCTTCCAGGGTCACTAACCCTTTCTAAG-3’ into the BglII site of pGL3-TK [10]. 
Similarly, the four-copy mutant IR1 construct p(mutNDRG2IR1)4-TK was generated by 
annealing 5’-GATCCTTAGAAAGAATTAGTGATTCTGGAA-3’ and 5’-
GATCTTCCAGAATCACTAATTCTTTCTAAG-3’. Plasmids expressing human retinoid X 
receptor  (RXR, NR2B1) and FXR into pSG5 have been previously described [10]. 
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Animal experiments 
 Experimental protocols with mice were performed with the approval of the animal ethics 
committee of the University of Barcelona (Spain). C57BL/6J mice and Fxr-null mice [11] (FXR-
/-, #007214) were obtained from The Jackson Laboratory (Bar Harbor, ME). 10-week-old male 
mice were injected i.p. with either vehicle (corn oil 5% DMSO) or GW4064 (GlaxoSmithKline, 
RTP, NC) dissolved in vehicle (10 mg/ml) at a dose of 50 mg/kg and then fasted for 8 h before 
sacrificed for tissue collection. Livers and kidney were excised, snap-frozen in liquid nitrogen 
and stored at -80 ºC. 
 
Cell culture and treatment conditions 
 Human hepatoma HepG2 and Huh7 cells and mouse hepatoma Hepa 1-6 cells were cultured 
in DMEM supplemented with 10% FBS. Mouse immortalized hepatocytes AML12 were grown 
in DMEM/Ham’s F-12 medium supplemented with 10% FBS, 100 mM dexamethasone, and ITS 
(Roche Applied Science). Human primary hepatocytes were obtained commercially (Ready 
HepsTM Fresh Hepatocytes, Lonza, Switzerland) and maintained in Hepatocyte Complete 
Medium (HCMTM bulletkit, Lonza). Cells were treated with ligands in the same medium 
supplemented with 10% charcoal stripped FBS (Biological Industries). For each experiment, 
duplicate or triplicate dishes were plated for each condition, as indicated in the figures.  
 
siRNA transfection 
 For siRNA-mediated FXR knockdown experiments, the human FXR siGENOME 
SMARTpool (M-003414-01) or siGENOME Non-Targeting siRNA #1 (D-001210-01) 
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(Dharmacon, Lafayette, CO) were used to transfect Huh7 cells in triplicate with the 
DharmaFECT 4 Transfection Reagent at a final concentration of 25 nM each for 48 h, followed 
by 24 h of treatments as described above. 
 
Adenoviral infection 
 Huh7 and Hepa 1-6 cells were infected at a multiplicity of infection (MOI) of 25 or 50 for 48h 
with adenoviruses expressing VP16 (AdVP16) or VP16FXR chimeras (AdVP16FXR) previously 
described [12]. 
 
Cell transfection and reporter assays 
 HepG2 cells were transiently transfected as previously described [10]. After 6h, cells were 
treated for 24 h with the vehicle (DMSO), 100 M CDCA, or 1 M GW4064. All transfections 
were performed in triplicate, and similar results were obtained in at least three independent 
experiments. 
 
Western blot analysis 
 Whole protein cell extracts were obtained from cultured cells or liver and kidney of mice. 
Cells were homogenized in Nonidet P-40 lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 1% 
Nonidet P-40) supplemented with a mixture of protease inhibitors and 0.1 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich). Equal amounts of protein (30-50 g) were run 
in 10% polyacrylamide gels, transferred onto Immobilon-P membranes (Millipore, Bedford, 
MA) and probed with antibodies: anti-NDRG2 (1:200, Abnova, cat# H00057447-M03); anti-
FXR (1:1000, Invitrogen, cat# A9033A); anti-actin (1:1000, Sigma-Aldrich, cat# A2066). 
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RNA isolation and real-time quantitative PCR analysis (QPCR) 
 Total RNA was isolated by using Tri-Reagent and was further treated with DNase I 
(Ambion). cDNA was synthesized from total RNA (1 g) by murine leukemia virus reverse 
transcriptase (Invitrogen) and p(dN)6 random primers (Roche Diagnostics). QPCR was 
performed using Platinum® Quantitative PCR SuperMix-UDG with ROX (Invitrogen) and 
TaqMan® Gene Expression Assay probes (Applied Biosystems): NDRG2, Hs00212263_m1; 
PLTP, Hs01067287_m1; NR0B2, Hs00222677_m1; NR1H4, Hs00231968_m1; Ndrg2, 
Mm00443483_m1; Nr0b2, Mm00442278_m1. Relative mRNA abundance was obtained by 
normalizing to 18S levels. 
 
In silico analysis of FXR response elements (FXREs) 
 The analysis of genomic sequences for the identification of putative FXREs was performed 
using NUBIScan computer algorithms (www.nubiscan.unibas.ch/). The alignment of sequences 
of different mammals was carried out using VISTA tools (genome.lbl.gov/vista/index.shtml). 
 
In vitro transcription/translation and electrophoretic mobility shift assay (EMSA) 
 Oligonucleotides corresponding to the sequence spanning nt +887 to +911 of Ndrg2 
(NDRG2IR1) were radiolabeled and used as probe as previously described [10]. For competition 
experiment, increasing fold molar excess of unlabeled probe NDRG2IR1, or a modified version 
harboring mutations in the IR1 hexamers (mutNDRG2IR1), were included during a 15 min 
preincubation on ice. A cold probe containing the FXRE of the human ileal-bile acid-binding 
protein (I-BABP) gene was used as a control as previously described [10]. 
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Chromatin immunoprecipitation (ChIP) assay 
 HepG2 cells were treated with 1% formaldehyde for 10 min, and then disrupted in lysis buffer 
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8) with protease inhibitors for 10 min. 
Chromatin was sonicated to shear DNA, precleared using Protein A/G PLUS Agarose (sc-2003, 
Santa Cruz Biotechnology), and immunoprecipitated overnight with 5 g of anti-FXR (sc-1204 
X, Santa Cruz Biotechnology) or goat IgG (I9140, Sigma-Aldrich). Precipitated DNA was 
extracted with phenol/chloroform and resuspended in 50 l of water. Input and 
immunoprecipitated DNA were subjected to PCR amplification using primers encompassing the 
FXRE in the proximal promoter of human NR0B2 (5’-AGCTAGTGATAAGGCACTTCC-3’ and 
5’-GTGGCACTGATATCACCTCAG-3’), the putative FXRE in the second intron of human 
NDRG2 (5’-CCTCTTACCTCCACATCAGC-3’ and 5’-ACACAGCAA CGAGGTGAATG-3’), 
or an unrelated genomic region from human alcohol dehydrogenase gene cluster lacking any 
functional FXRE (C. Langhi and J. C. Rodríguez, unpublished results) (5’-
AGGAGACATCGGATCTTCTGG-3’ and 5’-CTGTCATGCTAGCATCTCTCC-3’). PCR 
products were electrophoresed in agarose gel, visualized with ethidium bromide, quantified by 
ImageJ and normalized by input amplification. 
 
Statistical Analysis 
 Data are expressed as mean ± SEM as determined by analysis of multiple independent 
samples, as indicated in figure legends. Significant differences compared with the corresponding 
controls were assessed using a two-tailed Student’s t test. Values of p < 0.05 were considered to 
be significant. 
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RESULTS 
 
Human hepatic NDRG2 mRNA and protein levels are increased by FXR ligands 
 Microarray analysis revealed that expression of NDRG2 is up-regulated by FXR agonists (E. 
Pedraz and J. C. Rodríguez, unpublished data). To confirm this observation, human 
hepatocarcinoma Huh7 were treated with increasing concentrations of CDCA, a natural bile acid 
agonist of FXR, or GW4064, a synthetic FXR agonist, and the endogenous expression of 
NDRG2 was determined by QPCR. Treatment with both FXR ligands resulted in a dose-
dependent increase in the levels of NDRG2 mRNAs (Fig. 1A). To ensure that the induction of 
NDRG2 by FXR ligands is not limited to a single hepatoma cell line, we also analyzed RNA 
from HepG2 cells, obtaining similar results (Fig. 1B). In order to extend our results to a more 
physiologically relevant system, we treated human primary cultured hepatocytes. Both FXR 
agonists induced mRNA levels of NDRG2 and phospholipid transfer protein (PLTP), an 
established FXR target gene [13], to a similar extent (Fig. 1C). Next, Western blot analyses 
performed on whole cell lysates from Huh7 incubated with CDCA, GW4064, or vehicle revealed 
that the quantity of NDRG2 protein was robustly increased (15-fold) by both FXR ligands (Fig. 
1D). 
 
Induction of NDRG2 expression by CDCA and GW4064 requires FXR expression 
 Since bile acids may exert their actions through FXR-independent pathways, we silenced 
FXR by siRNA to determine whether the induction of NDRG2 expression observed upon 
treatment with CDCA was only dependent on FXR expression. Huh7 cells were therefore 
transfected with non-targeting siRNA or siRNA complexes directed against FXR (siFXR) before 
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ligand treatments. siFXR-mediated knock-down of endogenous FXR levels (Fig. 2A and B) 
completely blocked the induction of NDRG2 expression by CDCA (Fig. 2C). We also confirmed 
by siFXR the dependence on FXR in the response to GW4064. As a control, CDCA- and 
GW4064-dependent increase of the mRNA levels of NR0B2 (hereafter referred to as SHP), a 
previously characterized FXR target gene [14], was similarly attenuated in siFXR-transfected 
cells (Fig. 2C and D). 
 
Gain-of-function on FXR induces NDRG2 expression 
 We performed gain-of-function studies by ectopically expressing a chimera of FXR and 
transcriptional activator VP16 (VP16FXR) that is constitutively active. Infection of Huh7 cells 
with increasing MOIs of adenoviruses expressing VP16FXR resulted in a dose-dependent 
response induction of NDRG2 expression compared to VP16 alone (Fig. 2E). 
 
Mouse hepatic Ndrg2 expression is induced by activated FXR 
 Activation of FXR in AML12 cells, a non tumorigenic established cell line from mouse 
normal liver, strongly induced Ndrg2 mRNA levels (Fig. 3A). On the other hand, no induction of 
Ndrg2 expression was observed in mouse hepatoma Hepa 1-6 cells that do not expresses FXR 
(Fig. 3B and C). However, a significant induction of Ndrg2 expression was observed in Hepa 1-6 
when FXR was ectopically overexpressed (Fig. 3C and D). We next treated mice with either 
vehicle or 50 mg/kg of GW4064 for 8 h and determined liver NDRG2 protein levels by Western 
blot analysis. As shown in Fig. 3E, NDRG2 levels were significantly increased by GW4064 in 
vivo. Taken together, these expression data indicate that hepatic regulation of the NDRG2/Ndrg2 
gene by FXR shares a conserved mechanism between human and mouse. 
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Ndrg2 expression is induced by activated FXR in kidney 
 Given the roles of NDRG2 in renal function [4,5] and since both FXR and NDRG2 are 
enriched in kidney, we investigated whether Ndrg2 expression was regulated by FXR activation 
in this organ. The i.p. administration of GW4064 induced Ndrg2 expression in kidneys of wild 
type, but not FXR-/- mice (Fig. 3F). As expected, activation of FXR in vivo also increased Shp 
mRNA levels in the kidneys. In addition, we determined that GW4064 treatment markedly 
increased renal NDRG2 protein levels of wild type mice (Fig. 3G). 
 
Characterization of an IR1 element within intronic regions of NDRG2/Ndrg2 genes as a 
functional FXRE 
 Most known FXREs consist of an inverted repeat of the hexanucleotide motif RGGTCA with 
minor variants spaced by one nucleotide (IR1) [6]. Therefore, we scanned the 5’ flanking regions 
of human and mouse NDRG2/Ndrg2 genes for putative FXREs using the NUBIScan computer 
algorithm. However, no putative IR1 was identified in the region 10 kb upstream of the 
transcription start site (TSS) of any of these genes. Further in silico analysis of the intronic 
regions led to the identification, as the best hit, of a putative IR1 present within the second intron 
of human NDRG2 gene (at +1560 from TSS) and the first intron of murine Ndrg2 gene (at +894 
from TSS) that matched the consensus for FXREs (Fig. 4A). Sequence alignment using VISTA 
tools revealed that this IR1 is conserved in several mammalian species (Fig. 4B). 
 Treatment of transfected cells with natural (CDCA) or synthetic (GW4064) FXR agonists 
significantly increased luciferase activity of a reporter construct under the control of a 2.4-kb 
fragment of the Ndrg2 gene (p-437/+1966NDRG2) (Fig. 4C). Cotransfection of a FXR 
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expression plasmid robustly enhanced gene activation. Mutation of this IR1 element completely 
abolished the response to activated FXR (Fig. 4D). Next, this IR1 motif was tested in the context 
of heterologous promoter to evaluate whether it is sufficient to confer FXR-mediated regulation. 
Activated FXR enhanced the activity of Ndrg2 IR1-driven thymidine kinase (TK) promoter 
constructs in a copy-dependent manner, whereas a reporter construct with the TK promoter alone 
or with four copies of a mutated version of Ndrg2 IR1 was not stimulated at all (Fig. 4E). 
 EMSAs were performed using in vitro translated FXR and RXR and an oligonucleotide 
containing the Ndrg2 IR1 element. Neither FXR nor RXR alone bound to the probe (Fig. 4F, 
lanes 2 and 3), but a complex with the probe was formed when both proteins were present, 
indicating that the IR1 element is bound by FXR/RXR heterodimers (lane 4). The specificity of 
this retarded complex was demonstrated by competition analysis showing that it was competed 
away by increasing concentrations of either the unlabeled NDRG2IR1 probe (Fig. 4F, lanes 5-7) 
or a cold probe containing a well characterized IR1/FXRE from the I-BABP (Fig. 4F, lanes 11-
13), whereas it was relatively unaffected by the presence of the unlabeled DNA containing the 
mutated IR1 sequence (mutNDRG2IR1) (Fig. 4F, lanes 8-10). Furthermore, ChIP experiments 
demonstrated that FXR binds the identified NDRG2 IR1 in HepG2 cells (Fig. 4G). 
 
 
DISCUSSION 
 Our data show that NDRG2 expression is induced by bile acids. We have ascertained that 
these responses depend on FXR and do not require the synthesis of intermediate proteins. As 
demonstrated by mutation analysis in transient transfection and binding experiments, induction 
by FXR may be attributed to an IR1 located within intronic regions of human and murine genes. 
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Taken together, our results demonstrate that NDRG2 is a direct target of FXR. During the 
process of submitting our results for publication, Deuschle and colleagues have reported that 
FXR synthetic agonist PX20606 reduce liver tumor growth and metastasis in an orthotopic 
mouse xenograft model and proposed that NDRG2 partly mediates these effects [15]. These 
results are coincident to our current report in showing the induction of NDRG2 mRNA by FXR 
synthetic agonists in human hepatoma cell lines and livers of mice. Main data in the present 
study not addressed in that report include: a) results showing that natural bile acid CDCA 
induces NDRG2 expression (Fig. 1A-D) and knockdown experiments demonstrating that the 
physiological regulation of NDRG2 by bile acids absolutely requires FXR (Fig. 2C); b) induction 
of NDRG2 by FXR agonists in primary cultures of human hepatocytes (Fig. 1C); and c) 
induction of Ndrg2 expression in kidneys of wild type, but not FXR-/- mice (Fig. 3G). Notably, 
in addition to tumor suppression, NDRG2 has also been related to the regulation of sodium 
gradient in several reports. First, NDRG2 was identified as a mineralocorticoid-induced gene in 
renal cortical collecting duct, the site of aldosterone-regulated sodium absorption [4]. Later, 
studies in heterologous expression systems showed that co-expression of NDRG2 and ENaC 
resulted in a stimulation of ENaC-mediated Na+ currents [5]. More recently, Yao and co-workers 
have shown that NDRG2 directly binds and stabilizes the 1-subunit of Na+/K+-ATPase, the 
motor of sodium reabsorption [16]. Based on our data showing regulation of Ndrg2 expression 
by FXR in kidney, we believe that characterization of a potential role of FXR in regulating 
sodium reabsorption and fluid volume homeostasis is an interesting area of future investigation. 
 In conclusion, our results have demonstrated a direct link between bile acids and NDRG2, 
which may help in the elucidation of its physiological role. 
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FIGURE LEGENDS 
Fig. 1. Induction of NDRG2 expression by bile acid CDCA and a synthetic FXR agonist. 
Huh7 (A) and HepG2 (B) cells were treated for 24 h with vehicle (Control), or increasing 
concentrations of CDCA or GW4064. (C) Primary hepatocytes isolated from human liver were 
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incubated with vehicle (Control), 50 M CDCA, or 5 M GW4064 for 24 h. Total RNA was 
extracted and reverse transcribed for analysis by QPCR. Specific NDRG2 and PLTP mRNA 
levels normalized to 18S content are expressed relative to control set as 1 (mean ± SEM). (D) 
Huh7 cells were treated in triplicate dishes with vehicle (Control), 50 M CDCA, or 5 M 
GW4064 for 24 h, and 30 g of total protein lysates prepared from each dish were loaded in each 
lane for analysis by Western blot. Protein signals were quantified and NDRG2 levels were 
normalized to actin content. Significant differences compared with the corresponding controls 
are as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
Fig. 2. Studies with FXR silencing and gain-of-function. 
(A) Huh7 cells were transfected in triplicate for 48 h with either control siRNA (siControl) or 
siRNA targeting FXR (siFXR), and FXR mRNA expression levels were determined using 
QPCR. (B) Western blot analysis were performed with 30 g of total protein lysates prepared 
from two of the replicate dishes in each transfection condition (one dish per lane). (C-D) siRNA 
transfected Huh7 cells were treated with vehicle (Control), 50 M CDCA (C), or 5 M GW4064 
(D) for 24 h. (E) Huh7 cells were infected with increasing MOI of adenovirus expressing either 
VP16 (AdVP16) or a constitutively active chimera of VP16 and FXR (AdVP16FXR) for 48 h. 
Specific mRNA levels of FXR and NDRG2 were determined by QPCR, normalized to 18S 
content and expressed relative to control set as 1 (mean ± SEM). Significant differences 
compared with the corresponding controls are as follows: *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
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Fig. 3. Induction of mouse Ndrg2 expression by activated FXR. AML12 (A) and Hepa 1-6 
(B) cells were treated in triplicate dishes with vehicle (Control), 50 M CDCA, or 5 M 
GW4064 for 24 h. (C) Western blot analysis using an antibody against FXR and cell lysates from 
Huh7 and Hepa1-6 that were infected or not (No Ad) in duplicate with 50 MOI of adenovirus 
expressing either VP16 (AdVP16) or a chimera of VP16 and FXR (AdVP16FXR) for 48 h. Each 
lane was loaded with 30 g of total protein lysates prepared from individual dishes. (D) Relative 
mRNA levels of Ndrg2 in Hepa 1-6 infected in triplicate with 50 MOI of the indicated 
adenovirus. (E) Western blot analysis of cell lysates from livers of mice that were treated for 8 h 
with either vehicle (Control) (n=4) or 50 mg/kg GW4064 (n=5). Protein signals were quantified 
and NDRG2 levels were normalized to actin content. (F) Relative mRNA levels of Ndrg2 and 
Shp in kidneys of wild-type (WT) and FXR-/- mice that were treated as in (E) (n=5/group). (G) 
Renal protein levels of NDRG2 were determined by Western blot, and signals were quantified 
and normalized to actin. Significant differences compared with the corresponding controls are as 
follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
Fig. 4. Characterization of an intronic IR1 in NDRG2/Ndrg2 genes as an FXRE. (A) 
Schematic representation of exon-intron structure of human and mouse NDRG2/Ndrg2 genes and 
localization of the IR1 elements identified as FXREs. Empty boxes and black solid boxes 
indicate untranslated and translated regions of exons, respectively. (B) Comparison of sequences 
of different mammals. (C) HepG2 cells were transfected with a plasmid containing a luciferase 
reporter gene driven by a 2.4-kb fragment of the Ndrg2 gene or the empty pGL3-basic vector 
along with a plasmid expressing FXR or the empty pSG5 as control. Cells were treated with 
vehicle (Control), 100 M CDCA, or 1 M GW4064 for 24 h, and luciferase activities were 
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measured. (D) Experiments as in (C) using reporter construct containing wild-type or IR1 site-
directed mutated sequence, or the empty pGL3-basic vector, together with a plasmid expressing 
FXR or pSG5, in the presence of vehicle or 1 M GW4064. (E) Experiments as in (C) with 
reporter constructs containing 1, 2, or 4 copies of the wild-type (NDRG2IR1), or 4 copies of 
mutant (mutNDRG2IR1) Ndrg2 IR1 site in front of TK promoter-driven luciferase gene. Results 
are expressed as -fold induction over control. **, p < 0.01; ***, p < 0.001. (F) EMSAs were 
performed using in vitro transcribed/translated FXR, RXR, or unprogrammed reticulocyte 
lysate (–), and a labeled oligonucleotide containing the Ndrg2 IR1 element (NDRG2IR1). The 
FXR-RXR-FXRE complex is indicated by an arrow. Competition experiments for FXR-
RXRbinding were performed by adding a 50-, 200-, and 500-fold molar excess of unlabeled 
probes. Mutations in the modified version of wtNDRG2IR2 (mutNDRG2IR1) are shown in (D). 
I-BABP, FXRE of I-BABP gene [10]. (G) ChIP assays were performed with chromatin from 
HepG2 cells and either IgG or FXR-specific antibody and primers encompassing FXREs in 
human NDRG2 and SHP, as positive control, or an unrelated genomic region with no FXRE 
(Control), as negative control. 
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Highlights 
 Bile acid CDCA induces tumor suppressor NDRG2 expression in hepatocytes. 
 Induction of NDRG2 by bile acids require FXR expression. 
 An intronic FXR-response element was identified in human and murine genes. 
 FXR activation increases NDRG2 mRNA and protein levels in kidney. 
 We provide knowledge towards the understanding of NDRG2 physiological function. 
